Insight

Pietro De Placido: The SURVIVE Study will challenge the “no symptoms, no scan” BC surveillance model

Pietro De Placido/LinkedIn

Feb 26, 2025, 10:54

Pietro De Placido: The SURVIVE Study will challenge the “no symptoms, no scan” BC surveillance model

Pietro De Placido, Medical Oncologist at Dana-Farber Cancer Institute, a post on X about a paper by Kerstin Pfister et al. published in Journal of Clinical Oncology:

“The SURVIVE Study (NCT05658172) will challenge the ‘no symptoms, no scan’ BC surveillance model.

3,500 high-risk EBC patients will be randomized to standard vs. liquid biopsy-guided follow-up.

Costly if effective? Prevention beats cure.”

“The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer”

Authors: Kerstin Pfister, Sophia Huesmann, Thomas Friedl, Brigitte Rack, Wolfgang Janni et al.

Pietro De Placido: The SURVIVE Study will challenge the "no symptoms, no scan" BC surveillance model

More posts featuring Pietro De Placido.

Breast Cancer Brigitte Rack cancer Kerstin Pfister liquid biopsy OncoDaily Oncology Pietro De Placido Sophia Huesmann SURVIVE study Thomas Friedl Wolfgang Janni

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer